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similar difference was observed for Protocol-B. This finding showed non-weighted 
sampling from the SF would cause biases in CTS. At the same time, this result 
suggested that various CTS’s assumptions by weighted sampling might be useful. 
Further evaluation is recommended. ConClusions: The present study provides 
relevant information that there is considerable similarity in the demographics 
between SFs from Japanese HDB and Japanese CTs, suggesting usefulness of HDB 
with application of weighted sampling with CTS.
ReseaRch on Methods – Modeling Methods
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objeCtives: The UK runs a human papillomavirus (HPV) vaccination programme 
for girls aged 12-13 years to protect them from cervical cancer (CC). When long-
term health benefits such as these occur, with costs occurring at the outset, cost-
effectiveness analyses are very sensitive to the discount rate used. In view of this, 
the National Institute for Health and Care Excellence (NICE) will consider analyses 
with discount rates of 1.5% for costs and outcomes. Therefore, we modelled the 
cost-effectiveness of vaccination with the AS04-adjuvanted HVP-16/18 vaccine 
(BV) compared with HPV-6/11/16/18 (QV) with discount rates of 1.5%. Methods: 
A published lifetime Markov cohort model replicating the natural history of onco-
genic and low-risk HPV infection was adapted to the UK and run for a cohort of 
100,000 girls aged 12. Vaccine efficacy against vaccine-type and non-vaccine type 
HPV was obtained from each vaccine’s respective clinical trials. Lifetime protec-
tion was assumed for both vaccines. Input data were obtained from the literature, 
public databases and expert opinion. All costs were updated to 2012 values and 
reflected an NHS perspective. The incremental cost effectiveness ratio (ICER) of 
vaccinating with the BV vs. the QV was evaluated. Sensitivity analyses were per-
formed on key variables. Results: The model estimated that compared with QV, 
BV saved an additional 277 CIN1 cases, 1,460 CIN2/3 cases, 53 CC cases and 23 
deaths, but did not protect against 7,747 GW cases. Discounting at 1.5% results 
in +54 QALYs gained and £2.4 million saved. However, applying a discount rate 
of 3.5% results in -52 QALYs and £1.1 million saved. Sensitivity analyses showed 
results were robust. ConClusions: Applying a discount rate of 1.5% for both costs 
and outcomes focuses the appraisal on the long-term outcomes, such as CC and 
CC-death, of the vaccination programme, and to the finding that the BV was shown 
to dominate QV.
PRM61
InvestIgatIng the valIdIty of the uKPds outcoMes equatIons In 
cuRRent clInIcal PRactIce
McEwan P.1, Ward T.2, Bergenheim K.3
1Swansea University, Cardiff, UK, 2HEOR Consulting, Monmouth, UK, 3AstraZeneca, Mölndal, 
Sweden
objeCtives: The UKPDS 68 equations are routinely used to assess the benefits 
associated with glucose control in type 2 diabetes mellitus (T2DM) cohorts. Their 
validity has been questioned because they were derived from a cohort of newly 
diagnosed T2DM subjects and diabetes management practices have evolved consid-
erably. The objective of this study was to re-calibrate the equations to contemporary 
health care data and assess their continued relevance. Methods: We utilized data 
from The Health Improvement Network (THIN) database over the period 1/1/2004 
to 31/12/2009. We selected patients either aged > 64 years with HbA1c > 7.5% and 
diabetes duration > 10 years or aged > 55 years with at least 1 established cardiovas-
cular risk factor. Weibull survival equations were fitted to the following endpoints; 
myocardial infarction (MI), stroke, congestive heart failure (CHF), ischemic heart 
disease (IHD), amputation, blindness and end-stage renal disease (ESRD) using R. 
Missing data was modeled using multiple imputation. Results: Data were available 
on 68,990 T2DM subjects meeting the inclusion criteria with mean age 66.1 years, 
46% female, 8.8 years duration of diabetes; with mean body mass index (29.7m/kg2), 
HbA1c (8.0%), systolic blood pressure (147.5mmHg), total cholesterol (5.1mmol/l) 
and HDL cholesterol (1.3mmol/l). Log hazards (standard error) associated with unit 
changes HbA1c were 0.097(0.011) for MI, 0.084 (0.008) for CHF, 0.051 (0.009) for stroke, 
0.112(0.02) for blindness, 0.043 (0.007) for ESRD and 0.225 (0.017) for amputation. 
These estimates were statistically consistent (at the 95% level) with the original 
UKPDS log hazards except for IHD (non-significant in the THIN database) and ESRD 
(non-significant in UKPDS). ConClusions: In general, the UKPDS equations retain 
their validity for assessing the relationship between HbA1c and macrovascular and 
microvascular complications. It is likely that use of UKPDS equations will overesti-
mate the incidence of IHD and under-estimate the incidence of ESRD.
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objeCtives: Modelling chronic conditions such as diabetes necessitates the 
development of complex models, raising issues of computational intensity 
and execution time. While the use of compiled languages such as C++ is more 
computationally efficient, concerns may exist regarding their transparency 
compared to commonly used VBA in Microsoft Excel. This study investigates the 
application of antithetic variates to the pseudo-random numbers of Monte Carlo 
simulation, to provide reductions in stochastic uncertainty, through the introduc-
tion of negatively correlated pairs of simulation replicates, as a means of devel-
oping complex VBA models with reasonable computation times. Methods: A 
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objeCtives: Getting insight into the technical and logistical challenges of a typi-
cal global non-interventional EDC study by analyzing the pure log file numbers: 
from application scalability to data handling and processing. Methods: To analyze 
EDC activity and performance metrics, a global oncological observational study 
managed via the INTrial EDC application was selected. System log files were used 
for quantitative and qualitative performance/workflow-related aspects and time 
measurements. Results: Study parameters: The study ran for 4 years and was 
conducted in 39 countries with 6 languages, 382 sites, 3395 patients and 1612 users. 
The electronic Case Report Form for a single patient consisted of up to 2513 fields 
with a total number of 1,574,627 filled-in fields for the whole study. 24,382 transla-
tions were imported into the EDC system. Using 845 possible system queries per 
patient, 163,703 of these were commented and resolved, 30,451 manual queries were 
inserted. In total, 4,938,215 page calls took place for reading purpose and 582,052 for 
writing purpose (average of 3,781 page calls per day, 2.6 calls per minute). 6,060,981 
field entries or changes (value or status) were carried out (average: 4,151 changes 
per day). Performance: Time between real data collection and data entry by site: 
25% within 5 days, 22% from 6 to 20 days and 24% from 21 to 60 days. 92% of all 
manual queries had been commented by the site. Average time for resolving site 
comments for system queries: 29 days. Average time for translation processing: 19 
days. ConClusions: A suitable technical system like INTrial can help to improve 
and optimize the study workflows. Easy to use data entry and data management 
functionalities and additional tools like multi language support, translation import 
or archiving are substantial – always in combination with a well trained and enthu-
siastic study team and established procedures.
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objeCtives: The objective was to estimate the number of patients in Germany who 
received a 4-valent vaccine in 2011. This estimation was based on data collected 
through a sample of GP/Pediatrician practices (Vaccine Analyzer [VA] sample (0.43%; 
1.13%). Methods: The VA-sample was compared to the German population by age/
gender. This comparison shows a disproportional distribution of the VA-sample. A 
disproportional sample distribution may result in biases of final estimates. Hence, 
we opted for a methodology to mitigate estimation biases that would result from 
a straight-forward projection methodology. The VA-sample was restricted to eli-
gible practices. For the projection of the patient sample counts to the universe, a 
specific formula was used. The assumption is that the sampling ratio in terms of 
doses equals the sampling ratio in terms of patients. This assumption is theoreti-
cally valid as per medical recommendation one dose per patient shall be used. In 
summary, the estimation of total number of universe patients can be considered 
feasible from statistical point of view. Results: The methodology to estimate total 
patient numbers is statistically valid and utilizes data sources in an efficient way. 
The assumption with regard to the conversion of patients into doses is in line with 
empirical findings. The stratified projection caters to disproportional distribution 
of VA-sample doctors. ConClusions: The usage of patient age information from 
the VA-sample is theoretically feasible. The empirical validation with indepen-
dently sourced German Longitudial Prescription data of statutory insured patients 
shows differences, which is a certain weakness. As most vaccine-prescriptions are 
not patient-based the coverage is only 0.07% at paediatricians and 0.39% at GPs. 
However, VA-age distributions show an overall correlation of 80% which let the 
usage of VA-age distribution appears feasible. The suggested estimation method is 
methodologically sound and delivers results confirmed by observation, and statis-
tically preferable to straightforward projection methods which are prone to bias.
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objeCtives: Clinical trial simulation (CTS) is encouraged to prevent clinical tri-
als (CT) from failing. Health care database (HDB) is a potential source for baseline 
characteristics in CTS. The study evaluates, 1) overlapping between distribution of 
baseline characteristics extracted from Japanese HDB and also from two Japanese 
CTs for dyslipidaemia drugs, and 2) applicability of HDB as a sampling frame (SF) for 
baseline data in CTS for dyslipidaemia drug development. Methods: We extracted 
data from MinaCare HDB which contains both insurance claims and health check-
ups of people insured by employment-based insurances as of April 2013 and built 
two SFs according to eligibility criteria of the protocol in two CTs (Protocol-A and 
Protocol-B) conducted by Pfizer Japan Inc. Distribution of patient characteristics 
at screening, such as body mass index (BMI) and low density lipoprotein choles-
terol (LDL-C) levels, were compared between SFs (n= 1663 for Protocol-A, n= 5011 
for Protocol-B) from MinaCare HDB and CTs, for Protocol-A (n= 165) and Protocol-B 
(n= 459), respectively. Results: For both two protocols, we found similar distri-
bution of age, sex, weight, and BMI when comparing descriptive statistics (e.g., 
mean, standard deviation (SD)). However, LDL-C in CTs was higher than in SFs; e.g., 
in Protocol-A, patients without prescription for dyslipidaemia showed LDL-C 
(mg/dL) of 169.9±19.2 from the CT vs. 160.2±16.5 from the SF. Among the patients 
with prescription, LDL-C was 132.3±31.0 from the CT vs. 118.4±31.0 from the SF. A 
